5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006-2016)

Yannick J P G van den Biggelaar, Josephina G Kuiper, Maurice J C van der Sangen, Ernest J T Luiten, Sabine Siesling, Myrthe van Herk-Sukel, Adri C Voogd, Ilse Mesters*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Hormonal receptor (HR) positive breast tumors are common. Adjuvant hormonal therapy (AHT) with tamoxifen or Aromatase Inhibitors (AIs) is beneficial depending on the stage of the tumor. Despite the fact that AHT has been shown to improve survival and recurrence, Dutch adherence rates, which were mostly dependent on Tamoxifen prescriptions until 2006, plummeted from 80% after one year to 50% after five years. Nonadherence with AHT reduces its effectiveness. This research presents more recent adherence statistics (from 2006 to 2016), on a larger sample (7,996 vs 1,451), as well as factors that influence AHT adherence. In addition to tamoxifen data, AIs are now included. OBJECTIVE: As low use of adjuvant endocrine therapy is a potentially important and modifiable risk factor for poor outcome, it is important to monitor the rate as an indicator of women's burden of disease and the direction of adherence trends. METHODS: The Netherlands Cancer Registry (NCR) was used to find women with early-stage breast cancer who started AHT within a year of surgery and were linked to the PHARMO Database Network (n = 8,679). The Kaplan-Meier approach was used to measure AHT adherence five years after treatment was started, with a 60-day gap between refills as our primary outcome. Furthermore, the Medication Possession Rate (MPR) was determined using a cutoff of =80%. Analysis was performed on influential factors of adherence. RESULTS: The proportion of persistent women declined over time to reach 46.6% at the end of the fifth year and 53.3% of the women had a MPR =80% during the fifth year. Older and being diagnosed in 2006-2010 were associated with AHT adherence. CONCLUSION: Dutch 5-year AHT adherence appears to remain poor. Improving AHT adherence in HR+ breast cancer survivors is a critical medical need.
Original languageEnglish
Pages (from-to)331-339
Number of pages9
JournalBreast Disease
Volume42
Issue number1
DOIs
Publication statusPublished - 1 Jan 2023

Keywords

  • Breast cancer
  • adjuvant hormonal therapy
  • compliance
  • survival
  • survival analysis
  • Female
  • Humans
  • Breast Neoplasms/pathology
  • Antineoplastic Agents, Hormonal/therapeutic use
  • Treatment Outcome
  • Chemotherapy, Adjuvant
  • Tamoxifen/therapeutic use

Fingerprint

Dive into the research topics of '5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006-2016)'. Together they form a unique fingerprint.

Cite this